By Nick Johnstone22 November 2013
AstraZeneca’s decision to leave its Alderley Park R&D facility is a bitter blow to the local economy. Four bidders could provide an antidote.
You must be logged in to continue
Register for free to finish this article.
Sign up now for the following benefits:
To access this article REGISTER NOW
Would you like print copies, app and digital replica access too? SUBSCRIBE for as little as £6 per week.